Faculty
Inder M. Verma
Professor, Irwin and Joan Jacobs Chair in Exemplary Life Science
Laboratory of Genetics

Inder M. Verma, a professor in the Laboratory of Genetics and American Cancer Society Professor of Molecular Biology, is one of the world's leading authorities on the development of viruses for gene therapy vectors. Dr. Verma uses genetically engineered viruses to insert new genes into cells that can then be returned to the body, where they produce the essential protein whose absence causes disease.
Dr. Verma and Salk colleagues developed a gene therapy vector, based on a stripped-down version of HIV, that can deliver genes to non-dividing cells, which constitute the majority of the cells in our bodies. They have used this vector successfully to deliver the clotting factor gene to laboratory animals and to transfer a therapeutic gene to retinal cells to mice with an inborn deficiency. Dr. Verma's group is also studying two genes implicated in familial breast cancer, BRCA1 and BRCA2, and recently demonstrated that their action is linked to the cell's division cycle and that BRCA1 regulates gene activity.
Education
- M.Sc., Biochemistry Lucknow University, India
- Ph.D., Biochemistry, The Weizmann Institute of Science, Rehovot, Israel
- Postdoctoral fellow, Biology, (with David Baltimore), Massachusetts Institute of Technology
Awards and Honors
- NIH Outstanding Investigator Award, 1988
- The Third World Academy of Sciences
- National Academy of Sciences
- March of Dimes Birth Defects Foundation Franklin D. Roosevelt Investigator, 1997
- Institute of Medicine
- President, American Society for Gene Therapy, 2000-2001
Links
Salk News Releases
- The mouse with a human liver: a new model for the treatment of liver disease, February 22, 2010
- Salk technology at the heart of gene therapy success, November 6, 2009
- Genetic Re-disposition: Combined stem cell-gene therapy approach cures human genetic disease in vitro, June 1, 2009
- Salk Scientist Inder Verma to Receive 2009 Outstanding Achievement Award from American Society of Gene Therapy, May 29, 2009
- Salk Receives $6.6 Million Grant to Develop Stem Cell-Based Treatments for Incurable Diseases, April 30, 2009
- Inder Verma Named First Incumbent of the Irwin Mark Jacobs Chair in Exemplary Life Sciences, February 25, 2009
- Salk researchers develop novel glioblastoma mouse model, January 5, 2009
- Multi-tasking molecule holds key to allergic reactions, August 7, 2008
- PNAS article by Salk scientists wins 2007 Cozzarelli Prize, February 21, 2008
- Dr. Inder Verma Named Recipient of the 2008 Vilcek Foundation Prize, February 4, 2008
- New chimeric mouse model for human liver diseases, drug testing, December 3, 2007
- Salk Institute receives a $2.3 million stem cell research facility grant, June 7, 2007
- Salk researchers successfully deliver protein across the blood-brain barrier, May 15, 2007
- Salk scientists named 2006 AAAS Fellows, November 29, 2006
- Mouse study reveals human X-SCID gene therapy poses substantial cancer risk, April 26, 2006
- 'Fail safe' mechanism that helps keep inflammation in check, August 23, 2005
- Inflammation's Trigger Finger, July 21, 2004
- Male Sex Hormones Cooperate With Breast Cancer Gene To Suppress Tumors, Salk Scientists Find, June 9, 2003
- Gene Transfer Reduces Levels of Key Alzheimer\'s Disease Protein, March 25, 2003
- Gene Therapy Reverses Male Infertility In Salk-led Study, May 27, 2002
- Mice Cured Of Hemophilia By Salk Gene Therapy Protocol, March 29, 1999

